Pfizer suspends tanezumab studies in chronic pain

Tuesday 20 July 2010

At the request of the FDA, Pfizer Inc has suspended its clinical programme for tanezumab in chronic lower back pain and diabetic peripheral neuropathy. But studies will continue in areas of unmet medical need such as cancer pain.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States